Why Has US Launched a Trade Investigation Into Germany Over Drug Pricing?

The United States has launched a trade investigation into Germany's plans to reduce spending on pharmaceutical products, opening a new front in trade tensions between Washington and one of Europe's largest economies. The probe will examine whether Berlin's proposed policies are unreasonable or discriminatory toward US pharmaceutical companies and innovative drug manufacturers.

The investigation was announced by US Trade Representative Jamieson Greer under Section 301 of the Trade Act of 1974, a legal mechanism Washington has previously used to scrutinize trade practices in multiple countries. The move comes as Germany seeks to reform its healthcare system and address a projected funding shortfall estimated at €20 billion ($23 billion). ‘My Popularity Is None of Your Concern, Focus on Yours’: Giorgia Meloni Fires Back at Donald Trump.

Why Is the US Investigating Germany?

According to Greer, the investigation will focus on Germany's efforts to curb pharmaceutical spending through proposed healthcare reforms. The US Trade Representative's office will open a docket for written submissions on June 25, while its Section 301 Committee is scheduled to hold a public hearing on the matter in September.

Greer expressed concerns about the potential impact of Germany's proposed measures on innovative medicines. "I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals," Greer said. Donald Trump Repeats 'Begged for a Photo' Allegation Against Giorgia Meloni, Deepening US-Italy Rift.

US officials will examine whether the planned policies unfairly disadvantage American pharmaceutical companies that sell medicines in the German market.

Germany's Healthcare Reform Plans

The investigation follows proposals unveiled by Germany's Health Ministry in April aimed at restructuring the country's statutory healthcare system.

The reforms were designed to address a looming funding gap of approximately €20 billion and initially included plans for variable discounts on pharmaceutical products. However, those proposals have faced resistance from the pharmaceutical industry.

A German government source told Reuters earlier this week that the original plan involving variable drug discounts is being replaced after industry groups raised objections.

The German Embassy in Washington did not immediately respond to requests for comment following the US announcement.

What Is a Section 301 Investigation?

Section 301 of the US Trade Act of 1974 allows Washington to investigate foreign policies or practices that it believes may unfairly affect US commerce. The tool has been used in the past to examine trade practices in several countries and can ultimately lead to retaliatory measures, including tariffs or other trade restrictions.

The launch of a Section 301 investigation does not automatically result in penalties, but it creates a formal process through which US authorities can assess potential economic harm and determine possible responses.

Could Germany Face New Tariffs?

The outcome of the investigation could have broader trade implications. If US officials conclude that Germany's pharmaceutical pricing policies are unfair or discriminatory, Washington could consider tariff-related actions on German imports.

The probe comes amid a wider push by President Donald Trump's administration to use trade policy as a tool to address perceived imbalances and protect US industries.

Since returning to office last year, Trump has pursued an aggressive trade agenda that has included a 10% global tariff and threats of significantly higher duties on imports from countries including China and France.

Earlier this month, the administration proposed tariffs of up to 12.5% on imports from 60 countries following a separate Section 301 investigation into trade involving goods allegedly produced with forced labor.

Potential Impact on the Pharmaceutical Sector

The investigation is being closely watched by pharmaceutical companies, healthcare policymakers and trade analysts on both sides of the Atlantic. Germany is one of Europe's largest pharmaceutical markets and an important destination for innovative medicines developed by multinational drugmakers.

Any trade action resulting from the probe could affect market access, pricing policies and broader US-European trade relations, particularly in the healthcare sector.

For now, the investigation enters its public consultation phase, with written comments and hearings expected to shape the next steps before any final decision is made.

(The above story first appeared on LatestLY on Jun 21, 2026 07:06 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).